Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment

authors:

avatar Azadeh Haeri

Warning: No corresponding author defined!
Iranian Journal of Pharmaceutical Research : IJPR: Vol.16, issue 2; 411-412
article type: Editorial
DOI: https://doi.org/10.22037/ijpr.2017.2110

how to cite: Haeri A. Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment. Iran J Pharm Res. 2017;16(2):e125012. https://doi.org/10.22037/ijpr.2017.2110.

References

  • 1.

    Cerqueira BB, Lasham A, Shelling AN, Al-Kassas R. Nanoparticle therapeutics: technologies and methods for overcoming cancer. Eur. J. Pharm. Biopharm. 2015;97:140-51. [PubMed ID: 26515260].

  • 2.

    Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014;66:2-5. [PubMed ID: 24270007].

  • 3.

    Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15:1955-69. [PubMed ID: 24798476].

  • 4.

    Karimi M, Ghasemi A, Zangabad PS, Rahighi R, Basri SM, Mirshekari H, Amiri M, Pishabad ZS, Aslani A, Bozorgomid M, Ghosh D. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 2016;45:1457-501. [PubMed ID: 26776487].